Assessment of Systemic Corticosteroid Use in Individuals with Atopic Dermatitis: Findings from a US Population Study - Top-Institutions - MDSpire

Assessment of Systemic Corticosteroid Use in Individuals with Atopic Dermatitis: Findings from a US Population Study

  • By

  • Christopher G. Bunick

  • Ruth Ann Vleugels

  • Mark Lebwohl

  • April W. Armstrong

  • Ayman Grada

  • Emma Xiaomeng Yue

  • Madhi Saranadasa

  • Lani Wegrzyn

  • Elvira D’Andrea

  • February 22, 2026

  • 0 min

Share

Top Institutions in Dermatology

Brief introduction explaining scope and methodology.

  • #1

    National Institute of Allergy and Infectious Diseases (NIAID), NIH
    National Institute of Allergy and Infectious Diseases (NIAID), NIH

    Bethesda, MD

    Key Differentiators

    • Dermatology
    • Immunology
    • Clinical Research

  • #2

    Johns Hopkins University School of Medicine
    Johns Hopkins University School of Medicine

    Baltimore, MD

    Key Differentiators

    • Dermatology
    • Allergy and Immunology

  • #3

    University of Pennsylvania Perelman School of Medicine
    University of Pennsylvania Perelman School of Medicine

    Philadelphia, PA

    Key Differentiators

    • Dermatology
    • Clinical Immunology

  • #4

    Massachusetts General Hospital, Dermatology Department
    Massachusetts General Hospital, Dermatology Department

    Boston, MA

    Key Differentiators

    • Dermatology
    • Clinical Research

  • #5

    Stanford University School of Medicine
    Stanford University School of Medicine

    Stanford, CA

    Key Differentiators

    • Dermatology
    • Immunology

Original Source(s)

Assessment of Systemic Corticosteroid Use in Individuals with Atopic Dermatitis: Findings from a US Population Study

  • by Christopher G. Bunick, Ruth Ann Vleugels, Mark Lebwohl, April W. Armstrong, Ayman Grada, Emma Xiaomeng Yue, Madhi Saranadasa, Lani Wegrzyn, Elvira D’Andrea

  • February 22, 2026

Related Content

Lebrikizumab Meets Phase 3 End Points in Pediatric Atopic Dermatitis

In topline results from Lilly’s ADorable-1 trial, pediatric patients aged 6 months to 18 years had higher rates of skin clearance and itch improvement vs placebo, according to a press release from Eli Lilly and Company.

Efficacy of Upadacitinib in Treating Atopic Dermatitis in Sensitive Regions: Outcomes from a Multicenter Real-World Study on Hand, Head/Neck, and Genital Involvement

Correction: Retrospective Study on the Use of Brodalumab for Atopic Dermatitis Management: Real-World Insights